Mice with YUMMER1.7 melanomas and MC38 colorectal carcinomas treated with anti–PD-1/anti-MIF had trends toward slower tumor growth, more complete tumor regression, and prolonged survival when compared with those treated with monotherapy (anti–PD-1 or anti-MIF alone) or isotype control. Here, MIF is linked to melanoma.